Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.

Jakobsen JS, Laursen LG, Schuster MB, Pundhir S, Schoof E, Ge Y, d'Altri T, Vitting-Seerup K, Rapin N, Gentil C, Jendholm J, Theilgaard-Mönch K, Reckzeh K, Bullinger L, Döhner K, Hokland P, Fitzgibbon J, Porse BT.

Sci Adv. 2019 Jul 10;5(7):eaaw4304. doi: 10.1126/sciadv.aaw4304. eCollection 2019 Jul.

2.

Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes.

D'Altri T, Schuster MB, Wenzel A, Porse BT.

Eur J Haematol. 2019 Jun 29. doi: 10.1111/ejh.13286. [Epub ahead of print]

PMID:
31254415
3.

A new genetic tool to improve immune-compromised mouse models: Derivation and CRISPR/Cas9-mediated targeting of NRG embryonic stem cell lines.

Martin Gonzalez J, Baudet A, Abelechian S, Bonderup K, d'Altri T, Porse B, Brakebusch C, Juliusson G, Cammenga J.

Genesis. 2018 Sep;56(9):e23238. doi: 10.1002/dvg.23238.

PMID:
30010246
4.

β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1.

Gekas C, D'Altri T, Aligué R, González J, Espinosa L, Bigas A.

Leukemia. 2016 Oct;30(10):2002-2010. doi: 10.1038/leu.2016.106. Epub 2016 Apr 29.

PMID:
27125305
5.

Notch1 Pathway Activation Results from the Epigenetic Abrogation of Notch-Related MicroRNAs in Mycosis Fungoides.

Gallardo F, Sandoval J, Díaz-Lagares A, Garcia R, D'Altri T, González J, Alegre V, Servitje O, Crujeiras AB, Stefánsson ÓA, Espinet B, Hernández MI, Bellosillo B, Esteller M, Pujol RM, Bigas A, Espinosa L.

J Invest Dermatol. 2015 Dec;135(12):3144-3152. doi: 10.1038/jid.2015.328. Epub 2015 Aug 24.

6.

The Notch1 transcriptional activation domain is required for development and reveals a novel role for Notch1 signaling in fetal hematopoietic stem cells.

Gerhardt DM, Pajcini KV, D'altri T, Tu L, Jain R, Xu L, Chen MJ, Rentschler S, Shestova O, Wertheim GB, Tobias JW, Kluk M, Wood AW, Aster JC, Gimotty PA, Epstein JA, Speck N, Bigas A, Pear WS.

Genes Dev. 2014 Mar 15;28(6):576-93. doi: 10.1101/gad.227496.113.

7.

Hes repressors are essential regulators of hematopoietic stem cell development downstream of Notch signaling.

Guiu J, Shimizu R, D'Altri T, Fraser ST, Hatakeyama J, Bresnick EH, Kageyama R, Dzierzak E, Yamamoto M, Espinosa L, Bigas A.

J Exp Med. 2013 Jan 14;210(1):71-84. doi: 10.1084/jem.20120993. Epub 2012 Dec 24.

8.

Hematopoietic stem cell development requires transient Wnt/β-catenin activity.

Ruiz-Herguido C, Guiu J, D'Altri T, Inglés-Esteve J, Dzierzak E, Espinosa L, Bigas A.

J Exp Med. 2012 Jul 30;209(8):1457-68. doi: 10.1084/jem.20120225. Epub 2012 Jul 16.

9.

The Notch pathway in hematopoietic stem cells.

Bigas A, D'Altri T, Espinosa L.

Curr Top Microbiol Immunol. 2012;360:1-18. doi: 10.1007/82_2012_229. Review.

PMID:
22692832
10.

Hes1 expression and CYLD repression are essential events downstream of Notch1 in T-cell leukemia.

D'Altri T, Gonzalez J, Aifantis I, Espinosa L, Bigas A.

Cell Cycle. 2011 Apr 1;10(7):1031-6. Epub 2011 Apr 1.

11.

The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia.

Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J, Rodilla V, Inglés-Esteve J, Nomdedeu J, Bellosillo B, Besses C, Abdel-Wahab O, Kucine N, Sun SC, Song G, Mullighan CC, Levine RL, Rajewsky K, Aifantis I, Bigas A.

Cancer Cell. 2010 Sep 14;18(3):268-81. doi: 10.1016/j.ccr.2010.08.006.

Supplemental Content

Loading ...
Support Center